Novartis's Midostaurin To Fill 30 Year Void In AML Treatment
This article was originally published in Scrip
First Phase III data for Novartis AG's acute myeloid leukemia (AML) therapy midostaurin has hematologists excited as the drug "inches forward" towards a market approval – opening up the door for possible evolution of standard of care for AML patients, which has been sealed shut for the past 30 years.
You may also be interested in...
The company will talk to regulators in the US and Europe to see if the drug could be considered in elderly patients with low baseline peripheral white blood cells, who fared better than others in the failed SEAMLESS study.
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.